Program: KPI-150

KPI-150 is a novel peptide inhibitor of the Kv1.3 channel from the same family of compounds as ShK, which KPI Therapeutics is developing as a topical cream for atopic dermatitis, psoriasis, and other dermatological complications associated with inflammatory diseases.

KPI-150 targets the Kv1.3 channel on effector memory T cells, which are the subset of T cells that are found at the sites of inflammation in a variety of different autoimmune diseases, like atopic dermatitis. These T cells are involved in the pathogenesis of the disease. Blocking the Kv1.3 channel inhibits the effector functions of these effector memory T cells and helps ameliorate disease. We have shown through immunohistochemistry analysis that the infiltrating T cells in atopic dermatitis express high levels of the Kv1.3 channel and are thus a good target for KPI-150 treatment.

  • KPI-150 is in the ShK family of molecules from our Autoimmune Platform
  • KPI-150 topical cream for diseases like atopic dermatitis
  • Novel Kv1.3 channel target is immune sparing

Therapeutic Need - Atopic Dermatitis

Atopic Dermatitis is a chronic inflammatory autoimmune skin disease that affects over 15 million people in the USA alone. More than half of those patients are under the age of 20. The current treatment options such as moisturizers and corticosteroids only address the symptoms of the disease and stronger immunosuppressive drugs can have debilitating side effects. Even with current therapeutic options these patients still have many unmet needs.

  • Over 15 million people in the US have Atopic Dermatitis
  • Over 50% of patients are under the age of 20
  • Patients need safer and newer drugs that can be used long term

Development Status

We have shown that topical administration of KPI-150 works in a number of in vivo efficacy models. KPI-150 has demonstrated dose-dependent activity in an atopic dermatitis model where the drug was able to reduce inflammation, T cell infiltration, and markers of inflammation when applied topically. Based upon non-clinical models we anticipate KPI-150 will be well tolerated.

Drug formulation optimization and skin penetration assessments are ongoing to further develop KPI-150 for dermatologic applications.

  • Topical administration has been shown to work in various in vivo models reducing inflammation along with associated biomarkers
  • The ShK family is well tolerated as shown in our toxicology studies
  • KPI-150 is undergoing formulation optimization